Evolus Quarterly Income Statements Chart
Quarterly
|
Annual
Evolus Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | |||||||||||||||||||||||||||||||
| product revenue | 68,699,000 | 68,074,000 | 78,956,000 | 60,164,000 | 66,222,000 | 58,964,000 | 60,671,000 | 49,323,000 | 48,680,000 | 41,047,000 | 42,988,000 | 33,215,000 | 37,163,000 | 33,226,000 | 34,657,000 | 26,677,000 | 25,396,000 | 12,241,000 | 20,577,000 | 16,923,000 | |||||||||||
| service revenue | 688,000 | 448,000 | -9,000 | 921,000 | 687,000 | 369,000 | 328,000 | 696,000 | 666,000 | 674,000 | 658,000 | 684,000 | 682,000 | 702,000 | 738,000 | ||||||||||||||||
| total net revenues | 69,387,000 | 68,522,000 | 78,947,000 | 61,085,000 | 66,909,000 | 59,333,000 | 60,999,000 | 50,019,000 | 49,346,000 | 41,721,000 | 43,646,000 | 33,899,000 | 37,163,000 | 33,908,000 | 34,657,000 | 26,677,000 | 26,098,000 | 20,577,000 | 17,661,000 | ||||||||||||
| cost of goods sold | 24,067,000 | 21,867,000 | |||||||||||||||||||||||||||||
| gross profit | 45,320,000 | 46,655,000 | 6,235,500 | 12,807,000 | 5,858,000 | 6,277,000 | 15,811,000 | 9,449,000 | 1,651,000 | ||||||||||||||||||||||
| yoy | -60.56% | 35.54% | 254.82% | ||||||||||||||||||||||||||||
| qoq | -2.86% | -51.31% | 118.62% | -6.68% | -60.30% | 67.33% | 472.32% | ||||||||||||||||||||||||
| gross margin % | |||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||
| selling, general and administrative | 56,675,000 | 56,640,000 | 50,244,000 | 52,506,000 | 50,152,000 | 45,123,000 | 43,058,000 | 43,328,000 | 41,174,000 | 37,384,000 | 36,729,000 | 34,794,000 | 36,875,000 | 33,442,000 | 33,234,000 | 31,685,000 | 26,472,000 | 20,677,000 | 27,394,000 | 21,944,000 | 17,553,000 | 31,300,000 | 30,285,000 | 30,897,000 | 34,892,000 | ||||||
| research and development | 1,837,000 | 2,212,000 | 2,430,000 | 2,314,000 | 2,350,000 | 2,078,000 | 2,380,000 | 1,587,000 | 1,208,000 | 1,381,000 | 1,348,000 | 1,376,000 | 1,550,000 | 468,000 | 423,000 | 301,000 | 499,000 | 841,000 | 719,000 | 350,000 | 145,000 | 507,000 | 418,000 | 693,000 | 509,000 | 2,353,000 | 1,184,000 | 1,977,000 | 1,648,000 | 1,678,000 | |
| revaluation of contingent royalty obligation payable to evolus founders | -3,914,000 | 2,151,000 | 1,565,000 | 2,428,000 | 1,605,000 | 1,578,000 | -875,000 | 1,802,000 | 1,682,000 | 1,648,000 | 1,809,000 | 1,216,000 | 1,414,000 | 1,316,000 | 1,012,250 | 1,400,000 | 1,381,000 | 1,268,000 | -2,480,500 | -2,471,000 | 2,433,000 | -9,884,000 | 1,994,250 | 1,795,000 | 1,269,000 | ||||||
| depreciation and amortization | 932,000 | 824,000 | -1,581,000 | 1,087,000 | 1,427,000 | 1,409,000 | 1,373,000 | 1,311,000 | 1,247,000 | 1,202,000 | 1,027,000 | 920,000 | 853,000 | 922,000 | 920,000 | 923,000 | 1,746,000 | 2,033,000 | 1,876,000 | 1,744,000 | 1,658,000 | 1,749,000 | 1,468,000 | 1,202,000 | 978,000 | 484,000 | 2,000 | 3,000 | 4,000 | ||
| total operating expenses | 55,530,000 | 61,827,000 | -2,709,000 | 76,558,000 | 74,611,000 | 68,255,000 | 69,634,000 | 63,459,000 | 64,464,000 | 53,761,000 | 54,283,000 | 51,796,000 | 58,511,000 | 49,356,000 | 52,652,000 | 45,799,000 | 41,400,000 | 4,227,000 | 139,624,000 | 21,567,000 | 24,745,000 | 23,672,000 | 28,354,000 | 34,587,000 | 37,648,000 | 25,269,000 | 12,508,000 | 11,489,000 | 16,100,000 | 6,045,000 | |
| income from operations | -10,210,000 | -15,172,000 | -2,314,000 | -15,473,000 | -7,702,000 | -8,922,000 | -8,635,000 | -13,440,000 | -15,118,000 | -12,040,000 | -10,637,000 | -17,897,000 | -21,348,000 | -15,448,000 | -17,995,000 | -19,122,000 | -15,302,000 | 8,014,000 | -108,026,000 | -8,760,000 | -18,887,000 | -17,395,000 | -12,543,000 | -25,138,000 | -35,997,000 | -25,269,000 | -12,508,000 | -11,489,000 | -16,100,000 | -6,045,000 | |
| yoy | 32.56% | 70.05% | -73.20% | 15.13% | -49.05% | -25.90% | -18.82% | -24.90% | -29.18% | -22.06% | -40.89% | -6.41% | 39.51% | -292.76% | -83.34% | 118.29% | -18.98% | -146.07% | 761.25% | -65.15% | -47.53% | -31.16% | 0.28% | 118.80% | 123.58% | 318.01% | |||||
| qoq | -32.70% | 555.66% | -85.04% | 100.90% | -13.67% | 3.32% | -35.75% | -11.10% | 25.56% | 13.19% | -40.57% | -16.17% | 38.19% | -14.15% | -5.89% | 24.96% | -290.94% | -107.42% | 1133.17% | -53.62% | 8.58% | 38.68% | -50.10% | -30.17% | 42.46% | 102.02% | 8.87% | -28.64% | 166.34% | ||
| operating margin % | |||||||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||||
| interest income | 479,000 | 710,000 | 789,000 | 928,000 | 1,029,000 | 517,000 | 291,000 | 306,000 | 164,000 | 99,000 | 77,000 | 38,000 | 4,000 | 1,000 | 5,000 | 32,000 | 224,000 | 374,000 | 375,000 | 460,000 | 615,000 | 389,000 | |||||||||
| interest expense | -7,207,000 | -4,415,000 | -4,573,000 | -4,764,000 | -4,696,000 | -4,702,000 | -4,075,000 | -3,786,000 | -3,182,000 | -2,789,000 | -2,631,000 | -2,343,000 | -2,075,000 | -2,048,000 | -140,000 | -311,000 | -300,000 | -645,000 | -2,823,000 | -2,758,000 | -2,464,000 | -2,458,000 | -2,468,000 | -2,455,000 | -2,412,000 | -618,000 | -1,613,000 | 322,000 | 321,000 | 107,000 | |
| other income | -151,000 | 57,000 | -253,000 | 273,000 | 62,000 | 45,000 | 694,000 | 21,000 | 19,000 | -38,000 | 84,000 | -62,000 | -24,000 | -7,000 | |||||||||||||||||
| income before income taxes | -17,089,000 | -25,498,000 | |||||||||||||||||||||||||||||
| income tax expense | -53,000 | 72,000 | 440,000 | 134,000 | 43,000 | 47,000 | 106,000 | 24,000 | 23,000 | 57,000 | 12,000 | 28,000 | 10,250 | 19,000 | 12,000 | 10,000 | |||||||||||||||
| net income | -17,142,000 | -18,892,000 | -6,791,000 | -19,170,000 | -11,350,000 | -13,109,000 | -11,831,000 | -16,923,000 | -18,140,000 | -14,791,000 | -13,164,000 | -20,276,000 | -23,471,000 | -17,501,000 | -18,177,000 | -19,433,000 | -15,601,000 | 6,401,000 | -110,694,000 | -11,459,000 | -21,125,000 | -19,735,000 | -14,508,000 | -26,984,000 | -37,567,000 | -10,975,000 | |||||
| yoy | 51.03% | 44.11% | -42.60% | 13.28% | -37.43% | -11.37% | -10.13% | -16.54% | -22.71% | -15.48% | -27.58% | 4.34% | 50.45% | -373.41% | -83.58% | 69.59% | -26.15% | -132.43% | 662.99% | -57.53% | -43.77% | 79.82% | |||||||||
| qoq | -9.26% | 178.19% | -64.57% | 68.90% | -13.42% | 10.80% | -30.09% | -6.71% | 22.64% | 12.36% | -35.08% | -13.61% | 34.11% | -3.72% | -6.46% | 24.56% | -343.73% | -105.78% | 866.00% | -45.76% | 7.04% | 36.03% | -46.23% | -28.17% | 242.30% | ||||||
| net income margin % | |||||||||||||||||||||||||||||||
| other comprehensive income, net of tax: | |||||||||||||||||||||||||||||||
| currency translation adjustment | 240,000 | ||||||||||||||||||||||||||||||
| comprehensive loss | -16,902,000 | -18,826,000 | -7,007,000 | -19,258,000 | -11,394,000 | -13,239,000 | -11,652,000 | -17,061,000 | -18,192,000 | -14,870,000 | -13,133,000 | -20,479,000 | -23,533,000 | -18,177,000 | -19,433,000 | -15,601,000 | -110,697,000 | -11,475,000 | -21,331,000 | -19,516,000 | -14,521,000 | -27,008,000 | -37,515,000 | -10,984,000 | |||||||
| net income per share | -0.27 | -0.3 | -0.1 | -0.3 | -0.18 | -0.22 | -0.2 | -0.3 | -0.32 | -0.26 | -0.24 | -0.36 | -0.42 | -0.31 | -0.34 | -0.35 | -0.31 | 0.17 | -3.28 | -0.34 | -0.63 | -0.59 | -0.43 | -0.98 | -1.37 | -0.4 | -0.45 | -0.48 | -0.69 | -0.3 | |
| weighted-average shares outstanding used to compute basic and diluted net income per share | 64,539,291 | 63,696,627 | 62,016,853 | 63,148,968 | 62,724,604 | 58,797,311 | 56,918,721 | 57,023,151 | 56,920,260 | 56,475,572 | 56,065,297 | 56,176,949 | 56,079,569 | 49,773,101 | 55,007,132 | 51,150,063 | 33,737,838 | 33,748,690 | 33,732,754 | 33,720,436 | 28,237,816 | 27,470,558 | 27,408,774 | 27,330,174 | 24,402,368 | 24,768,581 | 23,687,866 | 20,226,460 | |||
| income before income taxes: | -18,820,000 | -6,351,000 | -19,036,000 | -11,307,000 | -13,062,000 | -11,725,000 | -16,899,000 | -18,117,000 | -14,768,000 | -13,107,000 | -20,264,000 | -23,443,000 | -17,503,000 | -7,158,250 | -19,433,000 | -15,601,000 | 6,401,000 | -13,023,000 | -11,486,000 | -21,127,000 | -19,479,000 | -22,606,250 | -27,133,000 | -37,794,000 | |||||||
| other comprehensive loss: | |||||||||||||||||||||||||||||||
| unrealized income, net of tax | 66,000 | ||||||||||||||||||||||||||||||
| product cost of sales | 13,841,750 | 18,223,000 | 19,077,000 | 18,067,000 | 19,270,000 | 15,431,000 | 14,712,000 | 12,146,000 | 13,370,000 | 13,490,000 | 15,819,000 | 13,208,000 | 15,834,000 | 11,490,000 | 11,302,000 | 4,908,000 | |||||||||||||||
| in-process research and development | 4,428,000 | 4,441,000 | 2,000,000 | ||||||||||||||||||||||||||||
| unrealized loss, net of tax | -216,000 | -88,000 | -44,000 | -130,000 | 179,000 | -138,000 | -52,000 | -79,000 | 31,000 | -203,000 | |||||||||||||||||||||
| income tax benefit | 23,000 | -150,000 | -27,000 | -2,000 | 256,000 | ||||||||||||||||||||||||||
| settlement payment from daewoong | -25,500,000 | ||||||||||||||||||||||||||||||
| income from extinguishment of debts | -968,000 | ||||||||||||||||||||||||||||||
| other comprehensive gain: | |||||||||||||||||||||||||||||||
| unrealized gain | -62,000 | 103,000 | |||||||||||||||||||||||||||||
| income tax (benefit) expense | -2,000 | -128,000 | -149,000 | -227,000 | -14,523,000 | ||||||||||||||||||||||||||
| comprehensive income | -17,398,000 | 6,401,000 | |||||||||||||||||||||||||||||
| weighted-average shares outstanding used to compute basic net income per share | 55,731,217 | 37,100,897 | |||||||||||||||||||||||||||||
| weighted-average shares outstanding used to compute diluted net income per share | 55,731,217 | 41,104,627 | |||||||||||||||||||||||||||||
| restructuring costs | 2,956,000 | ||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities, net of tax | -9,000 | ||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities, net of tax | -3,000 | -16,000 | -206,000 | 219,000 | -13,000 | -24,000 | 52,000 | ||||||||||||||||||||||||
| cost of sales | 2,755,250 | 4,854,000 | 1,948,000 | 4,219,000 | 1,094,500 | 3,718,000 | 660,000 | ||||||||||||||||||||||||
| net revenues | 7,806,000 | 10,496,000 | 3,869,500 | 13,167,000 | 2,311,000 | ||||||||||||||||||||||||||
| general and administrative | 17,519,000 | 12,222,000 | 7,209,000 | 6,248,000 | 3,467,000 | ||||||||||||||||||||||||||
| revaluation of contingent royalty obligation payable to evolus founders, a related party | 4,913,000 | 2,850,000 | 2,300,000 | 8,200,000 | |||||||||||||||||||||||||||
| income before taxes | -12,418,000 | -11,811,000 | -16,421,000 | -6,152,000 | |||||||||||||||||||||||||||
| net income and comprehensive loss | -12,442,000 | -11,830,000 | -16,433,000 | -6,162,000 | |||||||||||||||||||||||||||
| revaluation of contingent royalty obligation payable to related party | 900,000 |
We provide you with 20 years income statements for Evolus stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evolus stock. Explore the full financial landscape of Evolus stock with our expertly curated income statements.
The information provided in this report about Evolus stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.